517
Views
13
CrossRef citations to date
0
Altmetric
Drug Evaluation

Use of natalizumab in multiple sclerosis: current perspectives

, , , , , & show all
Pages 1151-1162 | Received 20 Mar 2016, Accepted 23 Jun 2016, Published online: 27 Jul 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Triantafyllos Doskas, Efthimios Dardiotis, George D. Vavougios, Konstantinos T. Ntoskas, Pinelopi Sionidou & Konstantinos Vadikolias. (2022) Stroke risk in multiple sclerosis: a critical appraisal of the literature. International Journal of Neuroscience 0:0, pages 1-21.
Read now
Dejan Jakimovski, Caila B Vaughn, Svetlana Eckert, Robert Zivadinov & Bianca Weinstock-Guttman. (2020) Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opinion on Drug Safety 19:9, pages 1121-1142.
Read now
Cristiano Pagnini, Kristen O. Arseneau & Fabio Cominelli. (2017) Natalizumab in the treatment of Crohn’s disease patients. Expert Opinion on Biological Therapy 17:11, pages 1433-1438.
Read now
Dejan Jakimovski, Bianca Weinstock-Guttman, Murali Ramanathan, Channa Kolb, David Hojnacki, Alireza Minagar & Robert Zivadinov. (2017) Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opinion on Biological Therapy 17:9, pages 1163-1172.
Read now

Articles from other publishers (9)

Luizat M. Abdullaeva, Bella I. Bursagova, Alexey L. Kurenkov & Lyudmila M. Kuzenkova. (2023) Treatment of multiple sclerosis in children: review of clinical trials. L.O. Badalyan Neurological Journal 4:1, pages 43-51.
Crossref
Dejan Jakimovski, Bianca Weinstock-Guttman & Robert Zivadinov. 2023. Translational Neuroimmunology, Volume 8. Translational Neuroimmunology, Volume 8 175 189 .
Dejan Jakimovski, Samreen Awan, Svetlana P. Eckert, Osman Farooq & Bianca Weinstock-Guttman. (2021) Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs 36:1, pages 45-59.
Crossref
Belén Rodríguez de Castro, Cristina Martinez-Múgica Barbosa, Aitor Ayastuy Ruiz & Beatriz Fernández González. (2021) Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis. European Journal of Hospital Pharmacy 28:2, pages 112-114.
Crossref
Janni Lisander Larsen, Jakob Schäfer, Helle Hvilsted Nielsen & Peter Vestergaard Rasmussen. (2020) Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis. BMJ Open 10:8, pages e037701.
Crossref
Dejan Jakimovski, Bianca Weinstock-Guttman, Murali Ramanathan, Michael G. Dwyer & Robert Zivadinov. (2020) Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines 8:1, pages 50.
Crossref
Hao Li, Fang-Hong Shi, Shi-Ying Huang, Shun-Guo Zhang, Zhi-Chun Gu & Ji-Fu Wei. (2018) Clinical adverse effects of natalizumab. Medicine 97:28, pages e11507.
Crossref
Maria Pia Amato, Antonio Bertolotto, Roberto Brunelli, Paola Cavalla, Benedetta Goretti, Maria Giovanna Marrosu, Francesco Patti, Carlo Pozzilli, Leandro Provinciali, Nicola Rizzo, Nicola Strobelt, Gioacchino Tedeschi, Maria Trojano & Giancarlo Comi. (2017) Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences 38:10, pages 1849-1858.
Crossref
Hao Wu & Jiangang Shen. (2016) Focusing on caveolin-1 in CNS autoimmune disease: multiple sclerosis. Neural Regeneration Research 11:12, pages 1920.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.